Straits Times Index
3,090.31 +17.32 (+0.56%) S&P 500
4,594.63 +26.83 (+0.59%) Dow
36,245.50 +294.60 (+0.82%) Nasdaq
14,305.03 +78.83 (+0.55%) Bitcoin USD
39,651.60 +139.84 (+0.35%) CMC Crypto 200
802.76 +11.20 (+1.41%)
Eupraxia Pharmaceuticals Inc. (EPRX.TO)
| Previous close | 5.39 |
| Open | 5.44 |
| Bid | 5.50 x N/A |
| Ask | 6.49 x N/A |
| Day's range | 5.39 - 5.79 |
| 52-week range | 3.27 - 9.10 |
| Volume | |
| Avg. volume | 23,606 |
| Market cap | 152.674M |
| Beta (5Y monthly) | 1.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.53 |
| Earnings date | 14 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.08 |
CNW GroupEupraxia Pharmaceuticals Reports Third Quarter 2023 Financial Results
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its financial results (prepared in accordance with International Financial Reporting Standards) and operational highlights for the third quarter ended September 30, 2023. All amounts are expressed in Canadian dollars unless otherwise indicated.
- CNW Group
Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of Rheumatology
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology, today announced late-breaking acceptance of the Company's abstract for a poster presentation at the 2023 Annual Meeting of the American College of Rheumatology.
- CNW Group
Eupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology, today announced the initiation of the second cohort for its Phase 1b/2a clinical trial in eosinophilic esophagitis ("EoE").
